6 results
IDSA 2017 CDiff Guidelines - Table 7. Potential Treatment Agents for Treatment of the Primary Clostridium difficile
IDSA 2017 CDiff ... Guidelines - Table ... Clostridium difficile infection ... Episode #Pharmacology ... #Antibiotics
GLP-1 Receptor Agonists - Pharmacology Summary
Mechanisms of Action: Stimulate glucose-dependent insulin release from the pancreas (GLP-1
Receptor Agonists - Pharmacology ... • Semaglutide ... Ozempic), or daily tablet ... #Summary #DM2 # ... diabetes #endocrinology
GLP-1 Agonists

Adlyxin (Lixisenatide) Daily
Bydureon (Exenatide ER) Weekly 
Ozempic (Semaglutide) Weekly 
Trulicity (Dulaglutide) Weekly 
Victoza (Liraglutide) Daily
Weekly Ozempic (Semaglutide ... being studied (semaglutide ... GLP1 #Agonists #Pharmacology ... #Dosing #Diabetes ... #DM2 #Endocrinology
Rybelsus (oral semaglutide) - First Oral GLP-1 Agonist
Dosing:
3 mg daily x 30 days, then 7 mg
GLP-1 Agonist Dosing ... oral route by using ... drug to remain stable ... #Diabetes #Pharmacology ... #Endocrinology
Diabetes Mellitus Type 2 Inpatient Medication Guide

Classes: Biguanide, Sulfonylurea, TZD, DPP-4 inhibitor, GLP-1 receptor agonist, SGLT2i,
of insulin and adjust ... Diabetes #Mellitus #DM2 ... #Medications #pharmacology ... #comparison #table ... #endocrinology
IDSA Recommendations for Treating Mycobacterium Tuberculosis Infection and Disease in HIV-AIDS
Treating LTBI (to prevent TB disease)
Indications:
IDSA Recommendations ... months or • RFB (dose ... Please refer to the table ... Guidelines for dosing ... #HIVAIDS #pharmacology